308 related articles for article (PubMed ID: 37969416)
21. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model.
Ni X; Yang J; Li M
Cancer Lett; 2012 Nov; 324(2):179-85. PubMed ID: 22617626
[TBL] [Abstract][Full Text] [Related]
22. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.
Desai NV; Sliesoraitis S; Hughes SJ; Trevino JG; Zlotecki RA; Ivey AM; George TJ
Cancer Med; 2015 Aug; 4(8):1224-39. PubMed ID: 25766842
[TBL] [Abstract][Full Text] [Related]
23. An update on treatment options for pancreatic adenocarcinoma.
Lambert A; Schwarz L; Borbath I; Henry A; Van Laethem JL; Malka D; Ducreux M; Conroy T
Ther Adv Med Oncol; 2019; 11():1758835919875568. PubMed ID: 31598142
[TBL] [Abstract][Full Text] [Related]
24. Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
Sarfraz H; Saha A; Jhaveri K; Kim DW
Curr Oncol; 2023 May; 30(6):5322-5336. PubMed ID: 37366887
[TBL] [Abstract][Full Text] [Related]
25. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
Cheng X; Zhao G; Zhao Y
Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
[TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
27. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
28. Systemic treatment of pancreatic cancer revisited.
Ducreux M; Seufferlein T; Van Laethem JL; Laurent-Puig P; Smolenschi C; Malka D; Boige V; Hollebecque A; Conroy T
Semin Oncol; 2019 Feb; 46(1):28-38. PubMed ID: 30638624
[TBL] [Abstract][Full Text] [Related]
29. Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes.
Akhuba L; Tigai Z; Shek D
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551952
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
32. Lipid metabolism in pancreatic cancer: emerging roles and potential targets.
Yin X; Xu R; Song J; Ruze R; Chen Y; Wang C; Xu Q
Cancer Commun (Lond); 2022 Dec; 42(12):1234-1256. PubMed ID: 36107801
[TBL] [Abstract][Full Text] [Related]
33. Hot topics in pancreatic cancer management.
Caputo D
World J Gastrointest Surg; 2023 Feb; 15(2):121-126. PubMed ID: 36896312
[TBL] [Abstract][Full Text] [Related]
34. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101.
Costa Neves M; Giakoustidis A; Stamp G; Gaya A; Mudan S
Cureus; 2015 Dec; 7(12):e435. PubMed ID: 26870619
[TBL] [Abstract][Full Text] [Related]
35. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
36. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.
Di Federico A; Mosca M; Pagani R; Carloni R; Frega G; De Giglio A; Rizzo A; Ricci D; Tavolari S; Di Marco M; Palloni A; Brandi G
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626033
[TBL] [Abstract][Full Text] [Related]
38. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
39. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
40. Primary advanced unresectable pancreatic cancer.
Wilkowski R; Wolf M; Heinemann V
Recent Results Cancer Res; 2008; 177():79-93. PubMed ID: 18084950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
